Investigating how cancer drugs affect blood vessel function
Modeling Tyrosine Kinase Inhibitor-Induced Vascular Dysfunction Using Human iPSCs
This study is looking into how cancer treatments called tyrosine kinase inhibitors (TKIs) can sometimes lead to heart problems, and it aims to find ways to reduce these risks for patients using advanced lab techniques.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11002950 on NIH RePORTER |
What this research studies
This research focuses on understanding the harmful effects of tyrosine kinase inhibitors (TKIs), which are used to treat cancer but can cause serious vascular issues like hypertension and heart attacks. By using human induced pluripotent stem cells (iPSCs), the researchers will explore the cellular mechanisms behind these side effects. They will employ advanced techniques, including CRISPR screening and multi-omics methods, to identify potential therapeutic targets that could mitigate these risks for patients undergoing TKI treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are currently receiving or will require treatment with tyrosine kinase inhibitors.
Not a fit: Patients who are not undergoing treatment with tyrosine kinase inhibitors or those with conditions unrelated to vascular dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies to prevent or treat vascular complications in cancer patients receiving TKI therapy.
How similar studies have performed: Previous research has shown promising results in understanding drug-induced vascular toxicity using similar cellular models, indicating potential for success in this approach.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Wu, Joseph C. — Stanford University
- Study coordinator: Wu, Joseph C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.